PRLD
NASDAQ HealthcarePrelude Therapeutics Incorporated - Common Stock
Biotechnology
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
�� 市场数据
| 价格 | $5.63 |
|---|---|
| 成交量 | 262,283 |
| 市值 | 448.40M |
| 贝塔系数 | 0.940 |
| RSI（14日） | 72.1 超买 |
| 200日均线 | $3.30 |
| 50日均线 | $4.53 |
| 52周最高 | $5.91 |
| 52周最低 | $0.83 |
| Forward P/E | -7.51 |
| Price / Book | 4.33 |
🎯 投资策略评分
PRLD 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (85/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 PRLD in your text
粘贴任何文章、记录或帖子 — 工具将提取 PRLD 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-08-17.